Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 396


Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial.

Suzuki K, Saji H, Aokage K, Watanabe SI, Okada M, Mizusawa J, Nakajima R, Tsuboi M, Nakamura S, Nakamura K, Mitsudomi T, Asamura H; West Japan Oncology Group; Japan Clinical Oncology Group.

J Thorac Cardiovasc Surg. 2019 Apr 9. pii: S0022-5223(19)30776-7. doi: 10.1016/j.jtcvs.2019.03.090. [Epub ahead of print]


Corrigendum to "Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer" [Lung Cancer 121 (July) (2018) Pages 37-40].

Nishio M, Nakagawa K, Mitsudomi T, Yamamoto N, Tanaka T, Kuriki H, Zeaiter A, Tamura T.

Lung Cancer. 2019 Jun;132:160. doi: 10.1016/j.lungcan.2019.04.012. Epub 2019 Apr 24. No abstract available.


BRAF Fusion - Another Mechanism of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors.

Mitsudomi T.

J Thorac Oncol. 2019 May;14(5):764-765. doi: 10.1016/j.jtho.2019.03.003. No abstract available.


Performance of Oncomine Fusion Transcript kit for formalin-fixed, paraffin-embedded lung cancer specimens.

Sakai K, Ohira T, Matsubayashi J, Yoneshige A, Ito A, Mitsudomi T, Nagao T, Iwamatsu E, Katayama J, Ikeda N, Nishio K.

Cancer Sci. 2019 Jun;110(6):2044-2049. doi: 10.1111/cas.14016. Epub 2019 May 3.


Honoring the Past, Embracing the Present, You Are the Future.

Scagliotti GV, Mitsudomi T, Mesko D.

J Thorac Oncol. 2019 Apr;14(4):571-573. doi: 10.1016/j.jtho.2019.01.012. Epub 2019 Mar 6. No abstract available.


Life-threatening complications after pulmonary resection for lung cancer in patients on chronic hemodialysis.

Tomizawa K, Sato K, Ohara S, Fujino T, Koga T, Nishino M, Kobayashi Y, Chiba M, Shimoji M, Suda K, Takemoto T, Mitsudomi T.

Surg Today. 2019 Jun;49(6):513-520. doi: 10.1007/s00595-019-1773-9. Epub 2019 Jan 31.


Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.

Wu YL, Planchard D, Lu S, Sun H, Yamamoto N, Kim DW, Tan DSW, Yang JC, Azrif M, Mitsudomi T, Park K, Soo RA, Chang JWC, Alip A, Peters S, Douillard JY.

Ann Oncol. 2019 Feb 1;30(2):171-210. doi: 10.1093/annonc/mdy554.


Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.

Koga T, Kobayashi Y, Tomizawa K, Suda K, Kosaka T, Sesumi Y, Fujino T, Nishino M, Ohara S, Chiba M, Shimoji M, Takemoto T, Suzuki M, Jänne PA, Mitsudomi T.

Lung Cancer. 2018 Dec;126:72-79. doi: 10.1016/j.lungcan.2018.10.019. Epub 2018 Oct 17.


Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro.

Nishino M, Suda K, Kobayashi Y, Ohara S, Fujino T, Koga T, Chiba M, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T.

Lung Cancer. 2018 Dec;126:149-155. doi: 10.1016/j.lungcan.2018.10.026. Epub 2018 Oct 31.


Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.

Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Jänne PA, Mann H, Cantarini M, Goss G.

Cancer. 2019 Mar 15;125(6):892-901. doi: 10.1002/cncr.31891. Epub 2018 Dec 4.


Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells.

Yonesaka K, Kobayashi Y, Hayashi H, Chiba Y, Mitsudomi T, Nakagawa K.

Oncol Rep. 2019 Feb;41(2):1059-1066. doi: 10.3892/or.2018.6881. Epub 2018 Nov 22.


Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights.

Kobayashi Y, Ambrogio C, Mitsudomi T.

Transl Lung Cancer Res. 2018 Aug;7(4):487-497. doi: 10.21037/tlcr.2018.07.04. Review.


CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer.

Suda K, Murakami I, Yu H, Kim J, Tan AC, Mizuuchi H, Rozeboom L, Ellison K, Rivard CJ, Mitsudomi T, Hirsch FR.

Mol Cancer Ther. 2018 Oct;17(10):2257-2265. doi: 10.1158/1535-7163.MCT-17-1279. Epub 2018 Jul 26.


Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9.

Hida T, Seto T, Horinouchi H, Maemondo M, Takeda M, Hotta K, Hirai F, Kim YH, Matsumoto S, Ito M, Ayukawa K, Tokushige K, Yonemura M, Mitsudomi T, Nishio M.

Cancer Sci. 2018 Sep;109(9):2863-2872. doi: 10.1111/cas.13721. Epub 2018 Jul 25.


Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions.

Suda K, Kim J, Murakami I, Rozeboom L, Shimoji M, Shimizu S, Rivard CJ, Mitsudomi T, Tan AC, Hirsch FR.

J Thorac Oncol. 2018 Oct;13(10):1496-1507. doi: 10.1016/j.jtho.2018.05.039. Epub 2018 Jun 19.


Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.

Nishio M, Nakagawa K, Mitsudomi T, Yamamoto N, Tanaka T, Kuriki H, Zeaiter A, Tamura T.

Lung Cancer. 2018 Jul;121:37-40. doi: 10.1016/j.lungcan.2018.04.015. Epub 2018 Apr 17. Erratum in: Lung Cancer. 2019 Jun;132:160.


The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer.

Lee CK, Lord S, Marschner I, Wu YL, Sequist L, Rosell R, Fukuoka M, Mitsudomi T, Asher R, Davies L, Gebski V, Gralla R, Mok T, Chih-Hsin Yang J.

J Thorac Oncol. 2018 Jun;13(6):792-800. doi: 10.1016/j.jtho.2018.03.010. Epub 2018 Mar 23.


EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.

Kobayashi Y, Fujino T, Nishino M, Koga T, Chiba M, Sesumi Y, Ohara S, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T.

J Thorac Oncol. 2018 May;13(5):727-731. doi: 10.1016/j.jtho.2018.01.009. Epub 2018 Feb 2.


[A Case of Resected Superior Sulcus Tumor with Pathological Complete Response after Trimodality Therapy].

Nishino M, Tomizawa K, Ohara S, Fujino T, Sesumi Y, Koga T, Sato K, Kobayashi Y, Chiba M, Shimoji M, Takemoto T, Mitsudomi T.

Gan To Kagaku Ryoho. 2018 Jan;45(1):103-105. Japanese.


CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials.

Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, de Marinis F, Felip E, Morabito A, Hodge R, Cantarini M, Johnson M, Mitsudomi T, Jänne PA, Yang JC.

Ann Oncol. 2018 Mar 1;29(3):687-693. doi: 10.1093/annonc/mdx820.


Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.

Mann H, Andersohn F, Bodnar C, Mitsudomi T, Mok TSK, Yang JC, Hoyle C.

Clin Drug Investig. 2018 Apr;38(4):319-331. doi: 10.1007/s40261-017-0611-3.


Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer.

Tomizawa K, Shimizu S, Ohara S, Fujino T, Nishino M, Sesumi Y, Kobayashi Y, Sato K, Chiba M, Shimoji M, Suda K, Takemoto T, Mitsudomi T.

Lung Cancer. 2017 Oct;112:57-61. doi: 10.1016/j.lungcan.2017.08.004. Epub 2017 Aug 4.


Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines.

Suda K, Rozeboom L, Furugaki K, Yu H, Melnick MAC, Ellison K, Rivard CJ, Politi K, Mitsudomi T, Hirsch FR.

Biomed Res Int. 2017;2017:7694202. doi: 10.1155/2017/7694202. Epub 2017 Oct 8.


S-1 as an option for second-line treatment of NSCLC. Is the 'East Side Story' applicable in the West?

Hayashi H, Mitsudomi T.

Ann Oncol. 2017 Nov 1;28(11):2627-2629. doi: 10.1093/annonc/mdx519. No abstract available.


Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.

Kinoshita T, Kudo-Saito C, Muramatsu R, Fujita T, Saito M, Nagumo H, Sakurai T, Noji S, Takahata E, Yaguchi T, Tsukamoto N, Hayashi Y, Kaseda K, Kamiyama I, Ohtsuka T, Tomizawa K, Shimoji M, Mitsudomi T, Asamura H, Kawakami Y.

Eur J Cancer. 2017 Nov;86:15-27. doi: 10.1016/j.ejca.2017.08.026. Epub 2017 Sep 23.


[Immune-Checkpoint Inhibitors for Lung Cancer with EGFR Mutation].

Hayashi H, Mitsudomi T.

Gan To Kagaku Ryoho. 2017 Sep;44(9):722-726. Japanese.


Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms.

Suda K, Rivard CJ, Mitsudomi T, Hirsch FR.

Expert Rev Anticancer Ther. 2017 Sep;17(9):779-786. doi: 10.1080/14737140.2017.1355243. Epub 2017 Jul 17. Review.


A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.

Hayashi H, Chiba Y, Sakai K, Fujita T, Yoshioka H, Sakai D, Kitagawa C, Naito T, Takeda K, Okamoto I, Mitsudomi T, Kawakami Y, Nishio K, Nakamura S, Yamamoto N, Nakagawa K.

Clin Lung Cancer. 2017 Nov;18(6):719-723. doi: 10.1016/j.cllc.2017.05.012. Epub 2017 May 25.


Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.

Suda K, Rozeboom L, Rivard CJ, Yu H, Ellison K, Melnick MAC, Hinz TK, Chan D, Heasley LE, Politi K, Mitsudomi T, Hirsch FR.

Lung Cancer. 2017 Jul;109:1-8. doi: 10.1016/j.lungcan.2017.04.010. Epub 2017 Apr 19.


Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.

Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T.

Lancet. 2017 Jul 1;390(10089):29-39. doi: 10.1016/S0140-6736(17)30565-2. Epub 2017 May 10.


Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer.

Jenkins S, Yang JC, Ramalingam SS, Yu K, Patel S, Weston S, Hodge R, Cantarini M, Jänne PA, Mitsudomi T, Goss GD.

J Thorac Oncol. 2017 Jul;12(7):1061-1070. doi: 10.1016/j.jtho.2017.04.003. Epub 2017 Apr 17.


Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.

Chiba M, Togashi Y, Bannno E, Kobayashi Y, Nakamura Y, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.

BMC Cancer. 2017 Apr 19;17(1):281. doi: 10.1186/s12885-017-3263-z. No abstract available.


Combined bevacizumab and erlotinib treatment in patients with lung cancer with the T790M resistance mutation.

Mitsudomi T.

Lancet Respir Med. 2017 May;5(5):369-370. doi: 10.1016/S2213-2600(17)30134-0. Epub 2017 Apr 10. No abstract available.


Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.

Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, Nonagase Y, Takahama T, Tanizaki J, Tanaka K, Yoshida T, Tanimura K, Takeda M, Yoshioka H, Ishida T, Mitsudomi T, Nishio K, Nakagawa K.

Ann Oncol. 2017 Jul 1;28(7):1532-1539. doi: 10.1093/annonc/mdx183.


Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.

Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T, Yang JC.

J Natl Cancer Inst. 2017 Jun 1;109(6). doi: 10.1093/jnci/djw279. Review.


Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells.

Sesumi Y, Suda K, Mizuuchi H, Kobayashi Y, Sato K, Chiba M, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T.

Lung Cancer. 2017 Feb;104:85-90. doi: 10.1016/j.lungcan.2016.12.012. Epub 2016 Dec 21.


Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation.

Suda K, Murakami I, Yu H, Kim J, Ellison K, Rivard CJ, Mitsudomi T, Hirsch FR.

J Thorac Oncol. 2017 Jun;12(6):1015-1020. doi: 10.1016/j.jtho.2017.02.002. Epub 2017 Feb 11.


Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status.

Suda K, Rozeboom L, Yu H, Ellison K, Rivard CJ, Mitsudomi T, Hirsch FR.

PLoS One. 2017 Feb 13;12(2):e0172209. doi: 10.1371/journal.pone.0172209. eCollection 2017.


[Molecular Biology for Surgical Treatment of Lung Cancer].

Suda K, Mitsudomi T.

Kyobu Geka. 2017 Jan;70(1):4-8. Japanese.


Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations.

Seow WJ, Matsuo K, Hsiung CA, Shiraishi K, Song M, Kim HN, Wong MP, Hong YC, Hosgood HD 3rd, Wang Z, Chang IS, Wang JC, Chatterjee N, Tucker M, Wei H, Mitsudomi T, Zheng W, Kim JH, Zhou B, Caporaso NE, Albanes D, Shin MH, Chung LP, An SJ, Wang P, Zheng H, Yatabe Y, Zhang XC, Kim YT, Shu XO, Kim YC, Bassig BA, Chang J, Ho JC, Ji BT, Kubo M, Daigo Y, Ito H, Momozawa Y, Ashikawa K, Kamatani Y, Honda T, Sakamoto H, Kunitoh H, Tsuta K, Watanabe SI, Nokihara H, Miyagi Y, Nakayama H, Matsumoto S, Tsuboi M, Goto K, Yin Z, Shi J, Takahashi A, Goto A, Minamiya Y, Shimizu K, Tanaka K, Wu T, Wei F, Wong JY, Matsuda F, Su J, Kim YH, Oh IJ, Song F, Lee VH, Su WC, Chen YM, Chang GC, Chen KY, Huang MS, Yang PC, Lin HC, Xiang YB, Seow A, Park JY, Kweon SS, Chen CJ, Li H, Gao YT, Wu C, Qian B, Lu D, Liu J, Jeon HS, Hsiao CF, Sung JS, Tsai YH, Jung YJ, Guo H, Hu Z, Wang WC, Chung CC, Lawrence C, Burdett L, Yeager M, Jacobs KB, Hutchinson A, Berndt SI, He X, Wu W, Wang J, Li Y, Choi JE, Park KH, Sung SW, Liu L, Kang CH, Hu L, Chen CH, Yang TY, Xu J, Guan P, Tan W, Wang CL, Sihoe AD, Chen Y, Choi YY, Hung JY, Kim JS, Yoon HI, Cai Q, Lin CC, Park IK, Xu P, Dong J, Kim C, He Q, Perng RP, Chen CY, Vermeulen R, Wu J, Lim WY, Chen KC, Chan JK, Chu M, Li YJ, Li J, Chen H, Yu CJ, Jin L, Lo YL, Chen YH, Fraumeni JF Jr, Liu J, Yamaji T, Yang Y, Hicks B, Wyatt K, Li SA, Dai J, Ma H, Jin G, Song B, Wang Z, Cheng S, Li X, Ren Y, Cui P, Iwasaki M, Shimazu T, Tsugane S, Zhu J, Jiang G, Fei K, Wu G, Chien LH, Chen HL, Su YC, Tsai FY, Chen YS, Yu J, Stevens VL, Laird-Offringa IA, Marconett CN, Lin D, Chen K, Wu YL, Landi MT, Shen H, Rothman N, Kohno T, Chanock SJ, Lan Q.

Hum Mol Genet. 2017 Jan 15;26(2):454-465. doi: 10.1093/hmg/ddw414.


Prognostic impact of pleural lavage cytology in patients with primary lung cancer.

Tomizawa K, Nishino M, Sesumi Y, Kobayashi Y, Sato K, Chiba M, Shimoji M, Suda K, Shimizu S, Sato T, Takemoto T, Mitsudomi T.

Lung Cancer. 2016 Dec;102:60-64. doi: 10.1016/j.lungcan.2016.10.009. Epub 2016 Oct 24.


Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.

Kobayashi Y, Azuma K, Nagai H, Kim YH, Togashi Y, Sesumi Y, Chiba M, Shimoji M, Sato K, Tomizawa K, Takemoto T, Nishio K, Mitsudomi T.

Mol Cancer Ther. 2017 Feb;16(2):357-364. doi: 10.1158/1535-7163.MCT-16-0407. Epub 2016 Dec 2.


Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib.

Azuma K, Hirashima T, Yamamoto N, Okamoto I, Takahashi T, Nishio M, Hirata T, Kubota K, Kasahara K, Hida T, Yoshioka H, Nakanishi K, Akinaga S, Nishio K, Mitsudomi T, Nakagawa K.

ESMO Open. 2016 Jul 21;1(4):e000063. eCollection 2016.


Clinical outcome of node-negative oligometastatic non-small cell lung cancer.

Sakai K, Takeda M, Hayashi H, Tanaka K, Okuda T, Kato A, Nishimura Y, Mitsudomi T, Koyama A, Nakagawa K.

Thorac Cancer. 2016 Nov;7(6):670-675. doi: 10.1111/1759-7714.12386. Epub 2016 Sep 12.


Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, Crino L, Satouchi M, Chu Q, Hida T, Han JY, Juan O, Dunphy F, Nishio M, Kang JH, Majem M, Mann H, Cantarini M, Ghiorghiu S, Mitsudomi T.

Lancet Oncol. 2016 Dec;17(12):1643-1652. doi: 10.1016/S1470-2045(16)30508-3. Epub 2016 Oct 14.


MEK inhibitors against MET-amplified non-small cell lung cancer.

Chiba M, Togashi Y, Tomida S, Mizuuchi H, Nakamura Y, Banno E, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.

Int J Oncol. 2016 Dec;49(6):2236-2244. doi: 10.3892/ijo.2016.3736. Epub 2016 Oct 17.


Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven?

Mitsudomi T, Kobayashi Y.

Transl Lung Cancer Res. 2016 Aug;5(4):446-9. doi: 10.21037/tlcr.2016.07.06. No abstract available.


Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.

Suda K, Bunn PA Jr, Rivard CJ, Mitsudomi T, Hirsch FR.

J Thorac Oncol. 2017 Jan;12(1):27-35. doi: 10.1016/j.jtho.2016.09.003. Epub 2016 Sep 15. Review.


FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.

Hibi M, Kaneda H, Tanizaki J, Sakai K, Togashi Y, Terashima M, De Velasco MA, Fujita Y, Banno E, Nakamura Y, Takeda M, Ito A, Mitsudomi T, Nakagawa K, Okamoto I, Nishio K.

Cancer Sci. 2016 Nov;107(11):1667-1676. doi: 10.1111/cas.13071.

Supplemental Content

Loading ...
Support Center